T0	Participants 600 631	patients with first-line NSCLC.
T1	Participants 659 814	ARIES enrolled patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology.
T2	Participants 815 951	Patients were required to provide informed consent and to have initiated bevacizumab with chemotherapy within 4 months before enrollment
T3	Participants 1167 1203	1967 patients with first-line NSCLC.
T4	Participants 1274 1367	Median age was 65 years (range, 31-93), and 252 patients (12.8%) identified as never smokers.
T5	Participants 1879 1929	real-world patient population with advanced NSCLC.